Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2025	Dec. 31, 2024
Current assets
Cash and cash equivalents	$ 76,497	$ 87,928
Marketable securities	210,344	203,509
Accounts receivable, net	24,624
Inventory	2,355
Prepaid expenses and other current assets	2,969	2,452
Total current assets	316,789	293,889
Long-term assets
Property and equipment, net	166	186
Operating lease right-of-use assets	2,434	2,798
Intangible assets, net	5,832	6,805
Long-term marketable securities	7,002	27,211
Other long-term assets	83	83
Total assets	332,306	330,972
Current liabilities
Accounts payable	6,216	8,882
Accrued compensation	6,267	4,776
Accrued clinical trial site costs	1,863	1,826
Operating lease liabilities	676	526
Accrued interest payable	409
Other current liabilities	5,512	2,737
Total current liabilities	20,943	18,747
Long-term liabilities
Contingent liability for Essentialis purchase price	18,859	14,791
Long-term debt, net	49,845	49,828
Long-term lease liabilities	2,248	2,472
Other long-term liabilities	271	21
Total liabilities	92,166	85,859
Commitments and contingencies (Note 6)
Stockholders’ equity
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.001 par value, 100,000,000 shares authorized, 50,437,066 and 45,703,811 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively	50	46
Additional paid-in-capital	740,746	696,966
Accumulated other comprehensive income	85	361
Accumulated deficit	(500,741)	(452,260)
Total stockholders’ equity	240,140	245,113
Total liabilities and stockholders’ equity	$ 332,306	$ 330,972